Is intravitreal bevacizumab (Avastin) safe? [PDF]
British Journal of Ophthalmology, 2006 Can a drug be safe if an FDA warning has been issued for it? Can a drug for which a Food and Drug Administration (FDA) warning has been issued be safe? The question of safety using off-label intravitreal bevacizumab (Avastin Genentech, South San Francisco, California, USA; Roche AG, Basle, Switzerland) is a concern among ophthalmologists around the ...
openaire +1 more source
Aggressive retinal astrocytoma associated with tuberous sclerosis
Clinical Ophthalmology, 2012 Machiko Tomida,1 Yoshinori Mitamura,1 Takashi Katome,1 Hiroshi Eguchi,1 Takeshi Naito,1 Takayuki Harada21Department of Ophthalmology, Institute of Health Biosciences, The University of Tokushima Graduate School, Tokushima, 2Visual Research Project, Tokyo
Tomida M +5 more
doaj
Comparing the effectiveness and costs of Bevacizumab to Ranibizumab in patients with Diabetic Macular Edema: A randomized clinical trial (the BRDME study) [PDF]
, 2015 Background: The effectiveness of ranibizumab in the treatment of diabetic macular edema has been proven with large clinical trials. For bevacizumab only two clinical trials have been published and a head-to-head comparison is lacking to date. However, if
Dijkgraaf, M.G.W. (Marcel) +9 more
core +1 more source
An eighteen-month follow-up study on the effects of intravitreal dexamethasone implant in diabetic macular edema refractory to anti-VEGF therapy [PDF]
, 2016 AIM: To evaluate the long-term efficacy and safety of dexamethasone implants in subjects affected by diabetic macular edema (DME) resistant to anti-vascular endothelial growth factor (VEGF) therapy. METHODS: Thirty-two DME patients were enrolled.
Carnovale, Anna +7 more
core +1 more source
Utilització de Bevacizumab en patologia diferent de la degeneració macular associada a l'edat [PDF]
, 2011 INTRODUCCIÓ L'angiogènesi és el procés que condueix a la formació de nous vasos sanguinis a partir de la vascularització preexistent. Disposem en l'actualitat de diversos fàrmacs que inhibeixen un factor proangiogènic, el factor de creixement de l ...
Cano Parra, Juan +4 more
core +1 more source
Optimizing Measurement of Vascular Endothelial Growth Factor in Small Blood Samples of Premature Infants [PDF]
, 2019 To establish a method that allows for the reliable assessment of vascular endothelial growth factor (VEGF-A) concentrations in very small blood samples of preterm infants. Systemic VEGF measurements are important in view of the most appropriate Anti-VEGF
Lopez Yomayuza, Claudia C. +3 more
core +1 more source
Intravitreal aflibercept versus bevacizumab for treatment of myopic choroidal neovascularization
Scientific Reports, 2018 The authors performed a retrospective and comparative study to compare the efficacy of intravitreal aflibercept and bevacizumab for patients with myopic choroidal neovascularization (mCNV).
Jia-Kang Wang +7 more
doaj +1 more source
Intravitreal bevacizumab for neovascular glaucoma [PDF]
Acta Ophthalmologica, 2010 Jost B, Jonas +3 more
openaire +2 more sources
Current Perspectives on the Use of Anti-VEGF Drugs as Adjuvant Therapy in Glaucoma [PDF]
, 2016 The approval of one of the first anti-vascular endothelial growth factor (VEGF) agents for the treatment of neovascular age-related macular degeneration one decade ago marked the beginning of a new era in the management of several sight-threatening ...
Andrés Guerrero, Vanessa +9 more
core +4 more sources
Intravitreal bevacizumab for macular edema due to branch retinal vein occlusion: 12-month results
Clinical Ophthalmology, 2011 Mehmet Demir, Ersin Oba, Gökhan Gulkilik, Mahmut Odabasi, Erhan OzdalSisli Etfal Training and Research Hospital, Eye Clinic, Sisli, Istanbul, TurkeyPurpose: To present the functional and anatomic changes after intravitreal bevacizumab in eyes ...
Demir M +4 more
doaj